Tracers / [131I]MEGMIB-5F7GGC
[131I]MEGMIB-5F7GGC
Also written as [I-131]MEGMIB-5F7GGC
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Anti-HER2 single domain antibody fragment (sdAb) radioiodinated via residualizing prosthetic agent
- Target / mechanism
- HER2 (human epidermal growth factor receptor 2) PMID 32448731
- Clinical application
- HER2-expressing tumors (e.g., ovarian carcinoma, as modeled by SKOV-3 xenografts) PMID 32448731
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | 45 ± 7% | >99% | Boc2-MEGMTB | 32448731 2021 Nucl Med Biol Conjugation of [131I]MEGMIB to monomeric/reduced 5F7GGC was performed adapting a previously reported method — Conjugation of [131I]MEGMIB with freshly reduced 5F7GGC was achieved in 45 ± 7% yield (n=10). |
Need this precursor?We can point you to suppliers for [131I]MEGMIB-5F7GGC, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32448731. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.